Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. Show more

Location: 3805 Old Easton Road, Doylestown, PA, 18902, United States | Website: https://aprea.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

9.569M

52 Wk Range

$1.41 - $5.01

Previous Close

$1.77

Open

$1.76

Volume

63,117

Day Range

$1.60 - $1.86

Enterprise Value

-8.617M

Cash

19.28M

Avg Qtr Burn

-3.313M

Insider Ownership

11.91%

Institutional Own.

40.94%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ATRN-119 Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

APR-1051 Details
Solid tumor/s, Cancer

Phase 1

Data readout

Eprenetapopt (APR-246) + azacitidine Details
Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Failed

Discontinued

APR-548 + azacitidine Details
Mutant Myelodysplastic Syndromes

Failed

Discontinued

Eprenetapopt (APR-246) + Azacitidine Details
Blood disorder, Myelodysplastic syndrome

Failed

Discontinued